Replies to post #6380 on Insmed Inc (INSM)

[TheFinalCD]

Now what
The only potential wrinkle in the data related to the drug's safety. The dropout rate for patients who used ALIS and GBT was 19.6%, which was a fair bit higher than the 9% dropout rate observed in the GBT group alone. Management stated that safety issues "were predominately mild or moderate in nature and generally declined after the second month of treatment."

To give investors more context on this issue, Dr. Paul Streck, Insmed's chief medical officer, offered this commentary:

The current guideline-based therapy to which we were compared in this study is not approved for the treatment of this disease, but is generally regarded as the best available option for these patients. Our drug candidate, ALIS, delivers high levels of an aminoglycoside directly to the lung macrophages and pulmonary tissue where the infection resides, and we believe this accounts for the significant impact on conversion that the drug demonstrated in these trial results.

All in all, today's clinical update clearly provides investors with reasons to be bullish on the future of Insmed. Risk-loving investors might want to consider putting this small-cap biotech on their watchlist.

[blueyedcatch]

Owned since 2005,I don`t pump. Stock is going up much higher than here,this is just the opener. I want to know about IPLEX,because if the company makes an announcement that IPLEX is free and clear of the lawsuit with Tercica/Genetec,then the we could have a monster run. It`s free and clear in October,the question is what rights do we own? Can we sell for short stature right away?Many questions,like can we take up where we left off on the MMD trial? Anyone know the answers?

[oxnous]

There is nothing like a short squeeze after great news top get the rocket going.